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Supplementary table 1- Participating studies from CIMBA 
Study Acronym Study Name Country
BCFR-AU Australian site of the Breast Cancer Family Registry Australia
KCONFAB Kathleen Cuningham Consortium for Research into Familial Breast Cancer Australia
VFCTG Victorian Familial Cancer Trials Group Australia
G-FAST Ghent University Hospital Belgium
BCFR-ON/OCGN Ontario site of the Breast Cancer Family Registry/Ontario Cancer Genetics Network Canada
INHERIT INterdisciplinary HEalth Research Internal Team BReast CAncer susceptibility Canada (Quebec)
MCGILL McGill University Canada (Quebec)
CBCS Copenhagen Breast Cancer Study Denmark
OUH Odense University Hospital Denmark
HEBCS Helsinki Breast Cancer Study Finland
GEMO Genetic Modifiers of cancer risk in BRCA1/2 mutation carriers France/USA
GC-HBOC German Familial Breast Group Germany
DKFZ German Cancer Research Center Germany/Pakistan/Colombia
DEMOKRITOS National Centre for Scientific Research Demokritos Greece
SMC Sheba Medical Centre Israel
CONSIT TEAM CONsorzio Studi ITaliani sui Tumori Ereditari Alla Mammella Italy
IOVHBOCS Istituto Oncologico Veneto Italy
PBCS Università di Pisa Italy
HEBON Hereditary Breast and Ovarian cancer study the Netherlands Netherlands
IHCC International Hereditary Cancer Centre Poland
NNPIO N.N. Petrov Institute of Oncology Russia
CNIO Spanish National Cancer Centre Spain
FPGMX Fundación Pública Galega de Medicina Xenómica Spain
HCSC Hospital Clinico San Carlos Spain
HVH University Hospital Vall d’Hebron Spain
ICO Institut Català d’Oncologia Spain
SWE-BRCA Swedish Breast Cancer Study Sweden
EMBRACE Epidemiological Study of Familial Breast Cancer UK
UKGRFOCR UK and Gilda Radner Familial Ovarian Cancer Registries UK/USA
BCFR-NC Northern California site of the Breast Cancer Family Registry USA
BCFR-NY New York site of the Breast Cancer Family Registry USA
BCFR-PA Philadelphia site of the Breast Cancer Family Registry USA
BCFR-UT Utah site of the Breast Cancer Family Registry USA
BIDMC Beth Israel Deaconess Medical Center USA
BRICOH Beckman Research Institute of the City of Hope USA
COH City of Hope Cancer Center USA
DFCI Dana Farber Cancer Institute USA
FCCC Fox Chase Cancer Center USA
GEORGETOWN Georgetown University USA
KUMC University of Kansas Medical Center USA
MAYO Mayo Clinic USA
MSKCC Memorial Sloane Kettering Cancer Center USA
NCI National Cancer Institute USA
NORTHSHORE NorthShore University HealthSystem USA
OSU CCG The Ohio State University Comprehensive Cancer Center USA
UCHICAGO University of Chicago USA
UCSF University of California San Francisco USA
UPENN University of Pennsylvania USA
UPITT Cancer Family Registry University of Pittsburg USA
UTMDACC University of Texas MD Anderson Cancer Center USA
WCP Women’s Cancer Program at Cedars-Sinai Medical Center USA
NRG_ONCOLOGY NRG Oncology USA/Australia
Supplementary table 2- Participating studies from BCAC 
Included in the analysis
Study Acronym Study Name Country Case-only Control-only
ABCFS Australian Breast Cancer Family Study Australia yes yes
ABCTB Australian Breast Cancer Tissue Bank Australia yes yes
BCEES Breast Cancer Employment and Environment Study Australia yes yes
MCCS Melbourne Collaborative Cohort Study Australia yes yes
LMBC Leuven Multidisciplinary Breast Centre Belgium yes yes
CBCS Canadian Breast Cancer Study Canada yes yes
MTLGEBCS Montreal Gene-Environment Breast Cancer Study Canada yes yes
OFBCR Ontario Familial Breast Cancer Registry Canada yes yes
CGPS Copenhagen General Population Study Denmark yes yes
HEBCS Helsinki Breast Cancer Study Finland yes yes
KBCP Kuopio Breast Cancer Project Finland yes yes
CECILE CECILE Breast Cancer Study France yes yes
BBCC Bavarian Breast Cancer Cases and Controls Germany yes yes
BSUCH Breast Cancer Study of the University of Heidelberg Germany yes yes
ESTHER ESTHER Breast Cancer Study Germany yes yes
GC-HBOC German Consortium for Hereditary Breast & Ovarian Cancer Germany yes yes
GENICA Gene Environment Interaction and Breast Cancer in Germany Germany yes yes
GEPARSIXTO
A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-
negative and HER2-positive early breast cancer
Germany no no
GESBC Genetic Epidemiology Study of Breast Cancer by Age 50 Germany yes yes
HABCS Hannover Breast Cancer Study Germany yes yes
MARIE Mammary Carcinoma Risk Factor Investigation Germany yes yes
PREFACE Evaluation of Predictive Factors regarding the Effectivity of Aromatase Inhibitor Therapy Germany no no
SKKDKFZS Städtisches Klinikum Karlsruhe Deutsches Krebsforschungszentrum Study Germany yes no
SUCCESSB Simultaneous Study of Gemcitabine-Docetaxel Combination adjuvant treatment Germany no no
SUCCESSC Simultaneous Study of Docetaxel Based Anthracycline Free Adjuvant Treatment Evaluation Germany no no
CCGP Crete Cancer Genetics Program Greece yes yes
BCINIS Breast Cancer In Northern Israel Study Israel yes yes
MBCSG Milan Breast Cancer Study Group Italy yes yes
ABCS Amsterdam Breast Cancer Study Netherlands yes yes
ORIGO Leiden University Medical Centre Breast Cancer Study Netherlands yes yes
RBCS Rotterdam Breast Cancer Study Netherlands yes yes
PBCS NCI Polish Breast Cancer Study Poland yes yes
SZBCS IHCC-Szczecin Breast Cancer Study Poland yes yes
HUBCS Hannover-Ufa Breast Cancer Study Russia yes yes
BREOGAN Breast Oncology Galicia Network Spain yes yes
HCSC Hospital Clinico San Carlos Spain yes no
KARBAC Karolinska Breast Cancer Study Sweden yes no
MISS Melanoma Inquiry of Southern Sweden Sweden yes yes
pKARMA Karolinska Mammography Project for Risk Prediction of Breast Cancer – Case-Control Study Sweden yes yes
SMC Swedish Mammography Cohort Sweden yes yes
BBCS British Breast Cancer Study UK yes yes
DIETCOMPLYF DietCompLyf Breast Cancer Survival Study UK yes no
POSH Prospective Study of Outcomes in Sporadic Versus Hereditary Breast Cancer UK yes no
SEARCH Study of Epidemiology and Risk factors in Cancer Heredity UK yes yes
UKBGS UK Breakthrough Generations Study UK yes yes
UKOPS UK Ovarian Cancer Population Study UK no yes
2SISTER The Two Sister Study USA yes no
BCFR-NY New York Breast Cancer Family Registry USA yes yes
BCFR-PA Philadelphia Breast Cancer Family Registry USA yes no
BCFR-UTAH Utah Breast Cancer Family Registry USA yes no
CPSII Cancer Prevention Study-II Nutrition Cohort USA yes yes
CTS California Teachers Study USA yes yes
MCBCS Mayo Clinic Breast Cancer Study USA yes yes
MEC Multiethnic Cohort USA yes yes
MMHS Mayo Mammography Health Study USA yes yes
MSKCC Memorial Sloan-Kettering Cancer Center Study USA yes no
NBHS Nashville Breast Health Study USA yes yes
NC-BCFR Northern California Breast Cancer Family Registry USA yes yes
NHS Nurses Health Study USA yes yes
NHS2 Nurses Health Study 2 USA yes yes
PLCO The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial USA yes yes
SISTER The Sister Study USA yes yes
UCIBCS UCI Breast Cancer Study USA yes yes
EPIC European Prospective Investigation Into Cancer and Nutrition (BPC3) Various yes yes
TNBCC Triple Negative Breast Cancer Consortium Study Various yes no
Supplementary Table 3- Number of case subjects per country and study 
Country BCAC Study Number of cases  CIMBA study Number of BRCA1 cases Number of BRCA2 cases
Australia MCCS 1051  NRG_ONCOLOGY 1 4
 ABCTB 951 KCONFAB 368 295
 ABCFS 1087 BCFR-AU 25 28
 BCEES 783 VFCTG 103 70
  Total : 3872 (6,42%)   Total : 497 (6,85%) Total : 397 (7,79%)
      
Belgium LMBC 789  G-FAST 121 76
  Total : 789 (1,31%)   Total : 121 (1,67%) Total : 76 (1,49%)
      
Canada CBCS 676  MCGILL 24 14
 OFBCR 1658 BCFR-ON 88 60
 MTLGEBCS 341 OCGN 71 64
   INHERIT 37 34
  Total : 2675 (4,43%)   Total : 220 (3,03%) Total : 172 (3,37%)
      
Denmark CGPS 1411  CBCS 76 64
   OUH 191 167
  Total : 1411 (2,34%)   Total : 267 (3,68%) Total : 231 (4,53%)
      
Finland HEBCS 281  HEBCS 53 67
 KBCP 556    
  Total : 837 (1,39%)   Total : 53 (0,73%) Total : 67 (1,31%)
      
France CECILE 306  GEMO 758 563
 EPIC 433    
  Total : 739 (1,23%)   Total : 758 (10,45%) Total : 563 (11,04%)
      
Germany ESTHER 296  GC-HBOC 1168 646
 SKKDKFZS 1091 DKFZ 36 14
 GESBC 351    
 GENICA 460    
 BBCC 441    
 MARIE 512    
 BSUCH 269    
 EPIC 661    
 GC-HBOC 3634    
 HABCS 929    
  Total : 8644 (14,33%)   Total : 1204 (16,59%) Total : 660 (12,95%)
      
Greece EPIC 182  DEMOKRITOS 132 23
 CCGP 670    
  Total : 852 (1,41%)   Total : 132 (1,82%) Total : 23 (0,45%)
      
Israel BCINIS 1330  SMC 66 33
  Total : 1330 (2,2%)   Total : 66 (0,91%) Total : 33 (0,65%)
      
Italy EPIC 822  CONSIT TEAM 271 187
 MBCSG 787 IOVHBOCS 109 113
   PBCS 49 6
  Total : 1609 (2,67%)   Total : 429 (5,91%) Total : 306 (6%)
      
Netherlands RBCS 473  HEBON 374 199
 EPIC 709    
 ORIGO 1055    
 ABCS 267    
  Total : 2504 (4,15%)   Total : 374 (5,15%) Total : 199 (3,9%)
      
Poland PBCS 1931  IHCC 77 0
 SZBCS 379    
  Total : 2310 (3,83%)   Total : 77 (1,06%) Total : 0 (0%)
      
Russia HUBCS 211  BIDMC 1 0
   NNPIO 44 2
  Total : 211 (0,35%)   Total : 45 (0,62%) Total : 2 (0,04%)
      
Spain BREOGAN 1376  HCSC 56 76
 EPIC 337 ICO 130 185
 HCSC 426 HVH 62 63
   FPGMX 67 44
   CNIO 31 33
   iovhbocs 1 0
  Total : 2139 (3,55%)   Total : 347 (4,78%) Total : 401 (7,87%)
Sweden SMC 1504  SWE-BRCA 190 25
 KARBAC 497    
 MISS 697    
 PKARMA 2991    
  Total : 5689 (9,43%)   Total : 190 (2,62%) Total : 25 (0,49%)
      
UK UKBGS 1632  OUH 1 0
 SEARCH 4057 EMBRACE 795 768
 POSH 1088 UKGRFOCR 13 4
 DIETCOMPLYF 711    
 BBCS 122    
 EPIC 703    
  Total : 8313 (13,78%)   Total : 809 (11,15%) Total : 772 (15,14%)
      
USA UCIBCS 490  BIDMC 43 24
 SISTER 2016 FCCC 26 11
 MEC 672 UTMDACC 25 39
 CTS 1156 NORTHSHORE 40 19
 NHS2 1606 DFCI 65 46
 NBHS 677 BRICOH 52 48
 MCBCS 925 WCP 51 18
 PLCO 868 NRG_ONCOLOGY 165 141
 CPSII 3054 OSU CCG 50 56
 BCFR-PA 132 KUMC 24 12
 MSKCC 120 UCSF 33 28
 2SISTER 1071 GEMO 84 25
 NHS 1590 BCFR-NC 33 22
 BCFR-UTAH 102 GEORGETOWN 5 0
 NC-BCFR 712 MAYO 122 74
 BCFR-NY 454 BCFR-PA 18 3
 TNBCC 373 NCI 42 21
 MMHS 384 COH 141 98
   BCFR-NY 37 25
   UPENN 240 168
   MSKCC 185 167
   BCFR-UT 67 54
   UCHICAGO 43 29
   UPITT 77 43
  Total : 16402 (27,19%)   Total : 1668 (22,98%) Total : 1171 (22,97%)
Total : 60326 Total : 7258 Total : 5100
Supplementary Table 4- Number of control subjects per country and study
Country BCAC Study Number of controls  CIMBA study Number of BRCA1 controls Number of BRCA2 controls
Australia MCCS 978  NRG_ONCOLOGY 3 6
 ABCTB 374 KCONFAB 356 273
 ABCFS 189 BCFR-AU 14 11
 BCEES 835 VFCTG 104 130
  Total : 2376 (5,18%)   Total : 477 (6,64%) Total : 420 (8,32%)
      
Belgium LMBC 1268  G-FAST 69 87
  Total : 1268 (2,76%)   Total : 69 (0,96%) Total : 87 (1,72%)
      
Canada CBCS 817  MCGILL 30 20
 OFBCR 375 BCFR-ON 34 24
 MTLGEBCS 169 OCGN 133 107
   INHERIT 52 46
  Total : 1361 (2,97%)   Total : 249 (3,47%) Total : 197 (3,9%)
      
Denmark CGPS 716  CBCS 111 65
   OUH 357 258
  Total : 716 (1,56%)   Total : 468 (6,51%) Total : 323 (6,4%)
      
Finland HEBCS 177  HEBCS 67 63
 KBCP 245 OUH 1 0
  Total : 422 (0,92%)   Total : 68 (0,95%) Total : 63 (1,25%)
      
France CECILE 159  GEMO 558 314
 EPIC 370    
  Total : 529 (1,15%)   Total : 558 (7,77%) Total : 314 (6,22%)
      
Germany ESTHER 187  GC-HBOC 675 407
 SKKDKFZS 0 DKFZ 19 10
 GESBC 181    
 GENICA 284    
 BBCC 253    
 MARIE 289    
 BSUCH 168    
 EPIC 650    
 GC-HBOC 1593    
 HABCS 866    
  Total : 4471 (9,74%)   Total : 694 (9,66%) Total : 417 (8,26%)
      
Greece EPIC 180  DEMOKRITOS 85 9
 CCGP 332    
  Total : 512 (1,12%)   Total : 85 (1,18%) Total : 9 (0,18%)
      
Israel BCINIS 713  SMC 99 47
  Total : 713 (1,55%)   Total : 99 (1,38%) Total : 47 (0,93%)
      
Italy EPIC 788  CONSIT TEAM 265 127
 MBCSG 366 IOVHBOCS 92 53
   PBCS 39 1
  Total : 1154 (2,51%)   Total : 396 (5,51%) Total : 181 (3,59%)
      
Netherlands RBCS 240  HEBON 491 401
 EPIC 676    
 ORIGO 660    
 ABCS 189    
  Total : 1765 (3,85%)   Total : 491 (6,83%) Total : 401 (7,95%)
      
Poland PBCS 2045  IHCC 121 0
 SZBCS 174    
  Total : 2219 (4,84%)   Total : 121 (1,68%) Total : 0 (0%)
      
Russia HUBCS 119  NNPIO 22 0
  Total : 119 (0,26%)   Total : 22 (0,31%) Total : 0 (0%)
      
Spain BREOGAN 725  HCSC 85 77
 EPIC 311 ICO 150 163
 HCSC 0 HVH 56 65
   FPGMX 41 0
   CNIO 32 31
   IOVHBOCS 0 26
  Total : 1036 (2,26%)   Total : 364 (5,07%) Total : 362 (7,17%)
      
Sweden SMC 709  SWE-BRCA 237 39
 KARBAC 0    
 MISS 1545    
 PKARMA 6084    
  Total : 8338 (18,17%)   Total : 237 (3,3%) Total : 39 (0,77%)
      
UK UKBGS 705  EMBRACE 908 867
 SEARCH 2670 UKGRFOCR 40 12
 POSH 0 VFCTG 0 1
 DIETCOMPLY
F
0   
 BBCS 442   
 EPIC 669   
 UKOPS 974   
  Total : 5460 (11,9%)   Total : 948 (13,19%) Total : 880 (17,44%)
      
USA UCIBCS 258  BIDMC 40 28
 SISTER 1558 FCCC 49 31
 MEC 724 UTMDACC 18 28
 CTS 610 NORTHSHORE 40 36
 NHS2 1905 DFCI 80 81
 NBHS 652 BRICOH 98 76
 MCBCS 221 WCP 137 51
 PLCO 858 NRG_ONCOLOGY 150 141
 CPSII 3029 OSU CCG 34 43
 BCFR-PA 0 KUMC 3 0
 MSKCC 0 UCSF 60 35
 2SISTER 0 GEMO 72 14
 NHS 1804 BCFR-NC 4 5
 BCFR-UTAH 0 GEORGETOWN 6 0
 NC-BCFR 148 MAYO 127 54
 BCFR-NY 27 BCFR-PA 26 3
 TNBCC 0 NCI 109 62
 MMHS 1635 COH 84 43
   BCFR-NY 25 27
   UPENN 220 178
   MSKCC 194 189
   BCFR-UT 135 97
   UCHICAGO 51 28
   UPITT 77 56
  Total : 13429 (29,26%)   Total : 1839 (25,59%) Total : 1306 (25,88%)
Total : 45888 Total : 7185 Total : 5046
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Supplementary figure 1- Heterogeneity in the SNP associations by country for the SNPs found to be associated with BRCA1 mutation status. Forest plots show the OR estimates in the
case-only regression analysis by country. The Likelihood ratio test for heterogeneity between countries was significant at p<0.05 for all SNPs. OR values were computed from a two sided
logistic regression using a 1df lrtest adjusted for age at BC diagnosis and the first four principal components. Data are presented as punctual OR values and confidence interval. Number
of individuals included for each country is detailed in Supplementary table 3. Source data are provided as a Source Data file.
Odds Ratios of association by country Odds Ratios of association by country Odds Ratios of association by country
Odds Ratios of association by country
rs5820435 rs11079012 rs58117746 rs80221606
Supplementary figure 2- Sensitivity analysis for the SNPs showing associations with BRCA1 mutation status in the case only analysis. Forest plots show the OR estimates of association
in the entire sample after excluding each country in turn. “Country” indicates the country excluded in the analysis. OR values were computed from a two sided logistic regression using a
1df lrtest adjusted for age at BC diagnosis and the first four principal components. Data are presented as punctual OR values and confidence interval. Source data are provided as a
Source Data file.
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Supplementary figure 3- Heterogeneity in the SNP associations by country for the SNPs found to be associated with BRCA2 mutation status. Forest plots show the OR estimates in the
case-only regression analysis by country. The Likelihood ratio test for heterogeneity between countries was significant at p<0.05 for all SNPs. OR values were computed from a two sided
logistic regression using a 1df lrtest adjusted for age at BC diagnosis and the first four principal components. Data are presented as punctual OR values and confidence interval. Source
data are provided as a Source Data file.
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Supplementary figure 4- Sensitivity analysis for the SNPs showing associations with BRCA2 mutation status in the case only analysis. Forest plots show the OR estimates of association
in the entire sample after excluding each country in turn. “Country” indicates the country excluded in the analysis. OR values were computed from a two sided logistic regression using a
1df lrtest adjusted for age at BC diagnosis and the first four principal components. Data are presented as punctual OR values and confidence interval. Source data are provided as a
Source Data file.
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Supplementary figure 5- Impact of the control-only analysis on the case-only analysis results 
Manhattan plot showing -log10(P-values) for the case-only analysis of SNPs before exclusion of the significant SNPs (i.e. in LD or ILD) in the control-only analysis (left) and after
exclusions of significant SNPs in the control-only analysis (right) for a. BRCA1 mutation carriers, N =  67,469 breast cancer cases (60,212 BCAC cases and 7,257 BRCA1 mutation
carrier cases)  and b. BRCA2 mutation carriers, N = 62,822 breast cancer cases (57,725 BCAC cases and 5,097 BRCA2 mutation carrier cases).  In red circles, example of SNPs excluded
based on control analysis and significantly associated in case-only analysis. Grey dotted line represents the multiple testing threshold, *=10-8. OR values were computed from a
two sided logistic regression using a 1df lrtest adjusted for age at BC diagnosis, country and the first four principal components. Source data are provided as a Source Data file.
